Charles River Laboratories Intl. Inc vs Endeavour Silver Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $302.17 (market cap $14.23B), while Endeavour Silver Corp trades at $8.66 (market cap $2.54B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 5.6× Endeavour Silver Corp's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Endeavour Silver Corp for 25 Days on average.
| CRL | EXK | |
|---|---|---|
Market Cap | $14.23B | $2.54B |
Volume | 1,176,885 | 7,077,330 |
Sector | Health | Basic Materials |
52-Week High | $310.77 | $14.12 |
52-Week Low | $149.93 | $7.07 |
Typical Hold Time | 33 Days | 25 Days |
Enterprise Value | $17.06B | $2.54B |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Endeavour Silver (EXK) trades at $8.72, up 4.81% today, showing mixed technical signals with bearish moving averages but neutral oscillators. The company demonstrates improving fundamentals with Q1 2026 earnings beating expectations and projected revenue growth from $468M to $737M in 2026. Recent operational developments include Terronera mine resumption and Kolpa expansion, though mechanical issues at Guanacevi mine present near-term challenges.
EXK presents a growth story with strong analyst support (78.57% buy rating) and improving profitability, but faces operational risks and high valuation multiples. The stock's outlook depends on successful mine execution and silver price stability, with technical resistance at $9.00 providing a near-term hurdle for further upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →